Literature DB >> 15316452

Tissue Doppler imaging in Fabry disease.

Maurizio Pieroni1, Cristina Chimenti, Andrea Russo, Matteo Antonio Russo, Attilio Maseri, Andrea Frustaci.   

Abstract

PURPOSE OF REVIEW: The development of effective enzyme replacement/enhancement therapy makes of clinical relevance considering Fabry disease in the differential diagnosis of patients with hypertrophic cardiomyopathy. In particular the opportunity to significantly modify the clinical progression of the disease has reinforced the need for early diagnosis of Fabry cardiomyopathy. RECENT
FINDINGS: The study with tissue Doppler of Fabry patients with endomyocardial biopsy-proven cardiac involvement showed a reduction of both diastolic and systolic myocardial velocities recorded at septal and lateral corners of mitral annulus. Tissue Doppler abnormalities were present not only in patients with left ventricular hypertrophy but also in younger patients with normal cardiac wall thickness and represent the first sign of myocardial damage. Furthermore tissue Doppler studies have been shown useful in detecting cardiac involvement in female carriers with no systemic manifestations of Fabry disease. In patients already submitted to enzyme-replacement therapy tissue Doppler and strain rate imaging represent useful noninvasive tools in assessing treatment efficacy.
SUMMARY: Tissue Doppler imaging can provide early detection of cardiac involvement in Fabry disease and represents the most accurate and sensitive noninvasive tool for the diagnosis of myocardial dysfunction and for the assessment of cardiac improvement during enzyme replacement therapy. The detection of tissue Doppler abnormalities in female carriers may represent a hint for an invasive assessment of cardiac involvement.

Entities:  

Mesh:

Year:  2004        PMID: 15316452     DOI: 10.1097/01.hco.0000131534.25034.43

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  5 in total

1.  Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease.

Authors:  Gregory Bierer; David Balfe; William R Wilcox; Zab Mosenifar
Journal:  J Inherit Metab Dis       Date:  2006-08       Impact factor: 4.982

Review 2.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

Review 3.  Cardiac Imaging in Anderson-Fabry Disease: Past, Present and Future.

Authors:  Roberta Esposito; Ciro Santoro; Giulia Elena Mandoli; Vittoria Cuomo; Regina Sorrentino; Lucia La Mura; Maria Concetta Pastore; Francesco Bandera; Flavio D'Ascenzi; Alessandro Malagoli; Giovanni Benfari; Antonello D'Andrea; Matteo Cameli
Journal:  J Clin Med       Date:  2021-05-06       Impact factor: 4.241

Review 4.  Striving towards the ideal cardiac functional assessment strategy: the contribution of tissue Doppler, strain and strain rate imaging.

Authors:  J C Mooman-Smook; P A Brink
Journal:  Cardiovasc J Afr       Date:  2007 Nov-Dec       Impact factor: 1.167

Review 5.  Anderson-Fabry disease in heart failure.

Authors:  M M Akhtar; P M Elliott
Journal:  Biophys Rev       Date:  2018-06-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.